Newleos, a new biotech with $93.5M, repurposes Roche’s experimental CNS drugs

Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, further demonstrating that the pharma-to-startup pipeline …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Equity raise and third-party capital update – Biotech Investments

Hardman & Co Research Hardman & Co Q&A on Duke Capital (DUKE): Equity raise and third-party capital update 20-Nov-2024 / 10:30 GMT/BST The issuer is

November 22, 2024

Novo acquires Inversago for up to $1 billion, spotlighting troubled weight loss approach

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled

August 10, 2023

Stilla Technologies with Source BioScience brings advanced genomics solutions to the UK market

Stilla Technologies, a global leader in digital PCR (dPCR) solutions, has announced a strategic partnership with Source BioScience, a leading UK-based genomics service provider.

November 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.